AbbVie Inc. has returned its rights to a MerTK inhibitor program licensed from originator Dong-A ST well over four years ago, marking a setback for the leading South Korean pharma firm’s plan to step up its novel immuno-oncology R&D.
Dong-A ST, an affiliate of Dong-A Socio Holdings , said in a stock market disclosure that it would retain...